Relay Therapeutics CFO’s Share Sale Signals Routine Liquidity Management, Not Distress
Relay Therapeutics CFO’s 17,717‑share sale is a routine liquidity move, not a sign of distress – still bullish on the company’s oncology pipeline and FDA milestones.
3 minutes to read